JCJoseph Minhow Chan

Joseph Minhow Chan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joseph Minhow Chan has a total of 814 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Osimertinib, platinum, and etoposide for patients with metastatic EGFR / TP53 / RB1 -mutant lung cancers at risk for histological transformation

    by Lena Morrill Gavarró, Monica F. Chen, Álvaro Quintanal Villalonga, Yufei Deng, Liancheng Lu, Britney Forsyth, Sahil Sahni, Eric G. Sun, Swanand Rakhade, Rania G. Aly, et al.

    Although EGFR inhibitors are highly effective for treating EGFR- mutant lung adenocarcinomas ( EGFR + LUADs), resistance inevitably emerges, with histologic transformation to small cell lung cancer (SCLC) representing a particularly aggressive mechanism. Our prospective trial enrolled patients with EGFR + LUAD at high risk of transformation ( TP53 / RB1 -deficient) and treated them with first-line osimertinib combined with platinum and etoposide. Despite the addition of SCLC-directed chemotherapy, nearly half of patients (5 of 11) underwent SCLC transformation, with median progression-free survival of 11 months and overall survival of 33 months. Genomic and single-cell transcriptomic profiling of patient samples revealed clinical and subclinical plasticity associated with TP53 / RB1 comutations, including histological transformation to SCLC, as well as mesenchymal and squamous histologies. These changes in plasticity were linked to progressive disruption of the RB pathway, leading to altered chromatin accessibility and induction of neuronal differentiation and epithelial-to-mesenchymal transition transcriptional programs, further intensified by osimertinib treatment. These findings provide insights into the role of plasticity in mediating drug tolerance.

  • Open Access

    ZFP36L2 orchestrates stress-adaptive plasticity in regeneration and cancer

    by Qingwen Jiang, Manisha S. Raghavan, Aileen M. Rodriguez, Morgan Lallo, Cyrus L. Tam, Saskia Hartner, Britney Forsyth, Ahmed Mahmoud, Fabian Zincke, Huiyong Zhao, et al.

    Phenotypic plasticity is a hallmark of cancer 1 ; however the molecular switches required for cell-fate reprogramming are poorly understood. During intestinal wound-healing and colorectal cancer (CRC) metastasis, differentiated cells can dynamically dedifferentiate into an intestinal stem cell (ISC) state to drive epithelial regeneration and metastatic outgrowth 2–10 . Here we show that the RNA-binding protein ZFP36L2, which is mutated in 5–10% of CRC 11–15 , is a pivotal stress-responsive orchestrator of dynamic dedifferentiation. In mouse colon regeneration models, ZFP36L2 ablation inhibits dedifferentiation, ISC gene expression and function and impairs intestinal regeneration. In human CRC, loss of ZFP36L2 function abrogates metastatic seeding and the outgrowth of LGR5 + canonical metastases while promoting lineage plasticity and non-canonical differentiation into heterogeneous cell states. Mechanistically, ZFP36L2 binds to stress-associated mRNAs that contain AU-rich 3′ untranslated regions, which induces the formation of dynamic biomolecular condensates associated with mRNA degradation and termination of the stress response. Together, these data show that ZFP36L2 acts as an important molecular switch that couples stress sensing with phenotypic plasticity. This in turn drives cellular dedifferentiation essential for re-establishing the ISC state during wound healing and metastasis. In ZFP36L2-deficient CRC, the inability to re-enter the LGR5 + state during metastatic outgrowth promotes non-canonical lineage plasticity, which is associated with poor clinical outcomes.


  • Open Access

    Hierarchical classification of immune cell transcriptomes at population-scale

    by Christopher Beltz, Zekai Qiu, Leon Sadowski, Joscha A. Kraske, Anmol Aggarwal, Alvaro Quintanal-Villalonga, Parvathy Manoj, Andrea Littbarski, Sunanjay Bajaj, Brigita Meškauskaitė, et al.

    Accurate immune cell classification is essential for interpreting single-cell RNA sequencing (scRNA-seq) data. However, progress in automating cell type annotation is constrained by the lack of independent, high-resolution benchmarks, as routine data integration introduces statistical dependencies that inflate model generalizability. Here, we present the single-cell universal classification omnibus (Suco), a resource of independent, uniform expert annotations, and Compocyte, a modular hierarchical classifier. Together, they establish a framework that substantially outperforms existing classifiers while facilitating expert review of ambiguous annotations. Applying Compocyte across 50 studies, including three newly generated datasets, we classified 15.6 million leukocytes from 3,965 patients. Within this cohort, we identified a new tumor-associated resorptive macrophage phenotype, a non-canonical monocyte subtype in subclinical cytokine release syndrome, and the programmatic erosion of T cell memory stemness across metastatic sites. Suco and Compocyte thus provide a generalizable framework to uncover the principles governing human immunity at population scale.


  • Open Access

    Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer

    by Yoojeong Seo, Shengzhe Zhang, Jinho Jang, Kyung-Pil Ko, Kee-Beom Kim, Yuanjian Huang, Dong-Wook Kim, Bongjun Kim, Gengyi Zou, Jie Zhang, et al.

    Small cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. Capping protein inhibiting regulator of actin dynamics ( CRACD ) that promotes actin polymerization, is frequently inactivated in SCLC. However, the role of CRACD loss in SCLC is unknown. Here we show that CRACD depletion drives neuroendocrine (NE) cell plasticity and immune evasion in SCLC. Mechanistically, CRACD inactivation disrupts actin organization, leading to suppression of Yap1-NOTCH signaling and subsequent NE gene upregulation. Simultaneously, CRACD loss drives EZH2-mediated histone methylation via nuclear actin disruption, leading to repression of MHC-I genes and depletion of CD8⁺ T cells. Consequently, CRACD-downregulated tumors exhibit increased cellular heterogeneity and escape from immune surveillance. Conversely, pharmacological inhibition of EZH2 restores MHC-I expression, reactivates antitumor immunity, and suppresses tumor growth. These findings identify CRACD as a tumor suppressor that constrains cell plasticity and immune evasion, highlighting the CRACD–EZH2–MHC-I axis as a potential therapeutic vulnerability in SCLC.


  • Top Cited Papers
    Open Access

    Basal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer

    by Abbie S. Ireland, Daniel A. Xie, Sarah B. Hawgood, Margaret W. Barbier, Lisa Y. Zuo, Benjamin E. Hanna, Scarlett Lucas-Randolph, Darren R. Tyson, Benjamin L. Witt, Ramaswamy Govindan, et al.

    Neuroendocrine and tuft cells are rare chemosensory epithelial lineages defined by the expression of ASCL1 and POU2F3 transcription factors, respectively. Neuroendocrine cancers, including small cell lung cancer (SCLC), frequently display tuft-like subsets, a feature linked to poor patient outcomes1,2,3,4,5,6,7,8,9. The mechanisms driving neuroendocrine–tuft tumour heterogeneity and the origins of tuft-like cancers are unknown. Using multiple genetically engineered animal models of SCLC, we demonstrate that a basal cell of origin (but not the accepted neuroendocrine origin) generates neuroendocrine–tuft-like tumours that highly recapitulate human SCLC. Single-cell clonal analyses of basal-derived SCLC further uncovered unexpected transcriptional states, including an Atoh1+ state, and lineage trajectories underlying neuroendocrine–tuft plasticity. Uniquely in basal cells, the introduction of genetic alterations enriched in human tuft-like SCLC, including high MYC, PTEN loss and ASCL1 suppression, cooperates to promote tuft-like tumours. Transcriptomics of 944 human SCLCs revealed a basal-like subset and a tuft–ionocyte-like state that altogether demonstrate notable conservation between cancer states and normal basal cell injury response mechanisms10,11,12,13. Together, these data indicate that the basal cell is a probable origin for SCLC and other neuroendocrine–tuft cancers that can explain neuroendocrine–tuft heterogeneity, offering new insights for targeting lineage plasticity.


  • Top Cited Papers
    Open Access

    ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer

    by Hirokazu Taniguchi, Subhamoy Chakraborty, Nobuyuki Takahashi, Avisek Banerjee, Rebecca Caeser, Yingqian A. Zhan, Sam E. Tischfield, Andrew Chow, Evelyn M. Nguyen, Álvaro Quintanal Villalonga, et al.

    Patients with small-cell lung cancer (SCLC) have poor prognosis and typically experience only transient benefits from combined immune checkpoint blockade (ICB) and chemotherapy. Here, we show that inhibition of ataxia telangiectasia and rad3 related (ATR), the primary replication stress response activator, induces DNA damage–mediated micronuclei formation in SCLC models. ATR inhibition in SCLC activates the stimulator of interferon genes (STING)–mediated interferon signaling, recruits T cells, and augments the antitumor immune response of programmed death-ligand 1 (PD-L1) blockade in mouse models. We demonstrate that combined ATR and PD-L1 inhibition causes improved antitumor response than PD-L1 alone as the second-line treatment in SCLC. This study shows that targeting ATR up-regulates major histocompatibility class I expression in preclinical models and SCLC clinical samples collected from a first-in-class clinical trial of ATR inhibitor, berzosertib, with topotecan in patients with relapsed SCLC. Targeting ATR represents a transformative vulnerability of SCLC and is a complementary strategy to induce STING-interferon signaling–mediated immunogenicity in SCLC.


  • Open Access

    ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer

    by Dan Li, Yu Zhan, Naitao Wang, Fanying Tang, Cindy J. Lee, Gabriella Bayshtok, Amanda R. Moore, Elissa W. P. Wong, Mohini R. Pachai, Yuanyuan Xie, et al.

    The mechanisms underlying ETS -driven prostate cancer initiation and progression remain poorly understood due to a lack of model systems that recapitulate this phenotype. We generated a genetically engineered mouse with prostate-specific expression of the ETS factor, ETV4, at lower and higher protein dosage through mutation of its degron. Lower-level expression of ETV4 caused mild luminal cell expansion without histologic abnormalities, and higher-level expression of stabilized ETV4 caused prostatic intraepithelial neoplasia (mPIN) with 100% penetrance within 1 week. Tumor progression was limited by p53-mediated senescence and Trp53 deletion cooperated with stabilized ETV4. The neoplastic cells expressed differentiation markers such as Nkx3.1 recapitulating luminal gene expression features of untreated human prostate cancer. Single-cell and bulk RNA sequencing showed that stabilized ETV4 induced a previously unidentified luminal-derived expression cluster with signatures of cell cycle, senescence, and epithelial-to-mesenchymal transition. These data suggest that ETS overexpression alone, at sufficient dosage, can initiate prostate neoplasia.


  • Open Access

    Table S2 from Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy

    by Alvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yuan Hao, Andrew Chow, Yingqian A. Zhan, Shweta S. Chavan, Fathema Uddin, Viola Allaj, Parvathy Manoj, Nisargbhai S. Shah, et al.

  • Open Access

    Table S2 from Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy

    by Alvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yuan Hao, Andrew Chow, Yingqian A. Zhan, Shweta S. Chavan, Fathema Uddin, Viola Allaj, Parvathy Manoj, Nisargbhai S. Shah, et al.

  • Open Access

    Figures S1 - S5 from Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy

    by Alvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yuan Hao, Andrew Chow, Yingqian A. Zhan, Shweta S. Chavan, Fathema Uddin, Viola Allaj, Parvathy Manoj, Nisargbhai S. Shah, et al.